# US 11,123,423 B2 · Zika virus vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,123,423 B2
- Document ID: US11123423B2
- Status: Granted
- Kind: B2
- Application number: 16/343,113
- Filed: 2017-10-19
- Published: 2019-08-22
- Granted: 2021-09-21
- Earliest claimed: 2016-10-19
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Sean P. J. Whelan; Sayantan Bose; Joseph Timpona
- Web page: https://patentgrep.com/patent/US11123423B2

## CPC

- A61K 39/205: Rhabdoviridae, e.g. rabies virus
- A61K 39/12: Viral antigens
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/5258: {Virus-like particles}
- C12N 2760/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/20223: Virus like particles [VLP]
- C12N 2760/20234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20241: Use of virus, viral particle or viral elements as a vector
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- C12N 2770/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24171: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods useful for treating and/or preventing a Zika virus infection are provided.

## Claims

### Claim 1

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, wherein the nucleic acid encoding the Zika virus E protein has a sequence that is at least 90% identical to SEQ ID NO:2.

### Claim 2

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, further comprising in its genome a nucleic acid sequence encoding a Zika virus precursor membrane (prM) protein or fragment thereof, wherein the nucleic acid encoding Zika virus prM has a sequence that is at least 90% identical to SEQ ID NO: 3.

### Claim 3

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, further comprising in its genome a nucleic acid sequence encoding a Zika virus precursor membrane (prM) protein or fragment thereof and a nucleic acid sequence encoding Zika virus capsid (C) protein or fragment thereof, wherein the nucleic acid encoding Zika virus capsid (C) protein has a sequence that is at least 90% identical to SEQ ID NO:4.

### Claim 4

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, wherein the genome of the recombinant VSV has a nucleic acid sequence that is at least 90% identical to SEQ ID NO:5.

### Claim 5

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, wherein the genome of the recombinant VSV has a nucleic acid sequence that is at least 90% identical to SEQ ID NO:6.

### Claim 6

A recombinant vesicular stomatitis virus (VSV) comprising in its genome a nucleic acid sequence encoding a Zika virus envelope (E) protein or fragment thereof, wherein the genome of the recombinant VSV has a nucleic acid sequence that is at least 90% identical to SEQ ID NO:7.